MBIO vs. INAB, FLGC, BCDA, GOVX, EQ, EDSA, MEIP, PRPH, GELS, and ME
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include IN8bio (INAB), Flora Growth (FLGC), BioCardia (BCDA), GeoVax Labs (GOVX), Equillium (EQ), Edesa Biotech (EDSA), MEI Pharma (MEIP), ProPhase Labs (PRPH), Gelteq (GELS), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry.
Mustang Bio vs.
IN8bio (NASDAQ:INAB) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
92.1% of IN8bio shares are owned by institutional investors. Comparatively, 9.9% of Mustang Bio shares are owned by institutional investors. 9.5% of IN8bio shares are owned by insiders. Comparatively, 0.2% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
IN8bio currently has a consensus price target of $6.00, indicating a potential upside of 4,445.45%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Mustang Bio.
Mustang Bio received 143 more outperform votes than IN8bio when rated by MarketBeat users. However, 74.29% of users gave IN8bio an outperform vote while only 64.26% of users gave Mustang Bio an outperform vote.
IN8bio is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
Mustang Bio's return on equity of 0.00% beat IN8bio's return on equity.
In the previous week, Mustang Bio's average media sentiment score of 1.08 beat IN8bio's score of -0.50 indicating that Mustang Bio is being referred to more favorably in the news media.
IN8bio has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.
Summary
IN8bio beats Mustang Bio on 9 of the 14 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
This page (NASDAQ:MBIO) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy MBIO Stock Free MBIO Stock Alerts